Elsevier has created a Monkeypox Information Center in response to the declared public health emergency of international concern, with free information in English on the monkeypox virus. The Monkeypox Information Center is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its monkeypox related research that is available on the Monkeypox Information Center - including this research content - immediately available in publicly funded repositories, with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the Monkeypox Information Center remains active.
Overcoming challenges en route to polio eradication

Contrary to claims by T Jacob John and Dhanya Dharmapalan,1 research demonstrates that poliovirus transmission predominantly follows the oral-faecal route,2 particularly in areas with poor sanitation, as is the case in many polio-affected countries. Either way, a full course of oral polio vaccine (OPV) is proven to effectively protect children from the virus.

Transitioning to exclusive use of inactivated polio vaccine (IPV) in settings with active transmission is not feasible given epidemiological and operational realities. While IPV provides strong individual protection, OPV can stop person-to-person transmission3 and is easier to administer in hard-to-access areas. These unique benefits outweigh the extremely rare chance of variant polioviruses.4 Thanks to OPV, the number of polio cases worldwide has been reduced by more than 99% since 1988— we cannot finish the job without it.

After achieving global eradication, use of OPV for routine immunisation will be stopped—a process that continues to be guided by independent global expert groups, including the Strategic Advisory Group of Experts on Immunization and the Global Commission for the Certification of Eradication of Poliomyelitis.

While previous deadlines have come and gone, the Global Polio Eradication Initiative’s 2022–2026 strategy1 has sharpened its approach to overcoming the remaining hurdles to eradication in the highest risk communities around the world. It is imperative that the programme receives the political and financial support it urgently needs to ensure that no child is ever again paralysed by this preventable disease.

1 I am WHO Director of Polio Eradication and Chair of the Global Polio Eradication Initiative Strategy Committee.

© 2022 World Health Organization. Published by Elsevier Ltd.

Aidan O’Leary
polionews@who.int
WHO, 1211 Geneva 27, Switzerland

1 John TJ, Dharmapalan D. Challenges en route to polio eradication. Lancet 2022; 400: 428–29.
2 Fine PEM, Camero IAM. Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative. Am J Epidemiol 1999; 150: 1001–21.
3 Hird TR, Grasly NC. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog 2012; 8: e1002599.
4 Jorba J, Diop OM, Iber J, et al. Update on vaccine-derived poliovirus outbreaks—worldwide, January 2018–June 2019. MMWR Morb Mortal Wkly Rep 2019; 68: 1024–28.
5 WHO. Polio eradication strategy 2022–2026: delivering on a promise. Geneva: World Health Organization, 2021.

Evolutionary consequences of delaying intervention for monkeypox

Since May, 2022, clusters of monkeypox infections have caused global concern. At present, this concern has been tempered by the fact that, even when uncontrolled, the number of infections is growing slowly, indicating a reproductive number (R) not much larger than unity. However, the effect of R on the probability of evolution might not be obvious. We suggest that, compared with zoonotic pathogens with large R values, those pathogens with R values just above 1, such as monkeypox virus, have a higher probability of evolution during the timeframe in which the number of cases remains low. Waiting until the number of cases is high would give monkeypox virus—or any emerging pathogen—the opportunity to adapt substantially to humans.

Population growth, ecological degradation, and climate change have increased the frequency of contact between humans and other animals, wild and domestic alike. The consequences include greater opportunities for pathogens to cross species barriers. Recent high-profile cases include Ebola virus (from bats), MERS coronavirus (bats or camels), SARS-CoV-1 and SARS-CoV-2 (bats), and monkeypox (rodents). After a zoonosis spills over into humans, subsequent evolution of the virus results in higher transmission, making control more difficult, and causing unpredictable changes in disease severity, as seen with different variants in the ongoing SARS-CoV-2 pandemic.

By definition, a zoonosis primarily infects non-humans. Any such pathogen is unlikely to be optimised for growth and transmission in humans, and substantial fitness increases are therefore possible. Retrospective phylogenetic analysis of the large Ebola outbreak from 2013 to 2016 revealed a small number of amino acid changes associated with increases in in-vitro growth in cell culture and transmission in the population.3 The delta and omicron variants of SARS-CoV-2 contain extensive mutations, as illustrated in NextStrain,7 and are associated with increases in effective R.3 Similarly, the current monkeypox infections found both geographically and mutationally distant from the probable origin in Nigeria are consistent with adaptation by the pathogen for greater human-to-human transmission.4

These examples notwithstanding, gathering data on the evolution of newly emerging pathogens is challenging because it is harder to detect a small early-stage outbreak than a bigger later-stage outbreak. Advances in technologies such as wastewater sampling and the plummeting cost of sequencing pathogen genomes offer a promising way forward, but sampling still requires substantial public health resources. Is the use of these resources worth the effort?

Models provide a means to investigate this question by integrating pathogen epidemiological and
Correspondence

1

2

1·8

2·0

1·6

1·8

1·6

1·2

1·4

1·4

2·0

N before intervening, lower R0 has greater probability of evolving. R0 = basic chain length and total number of infected individuals, so, when waiting for a given patterns hold in general when waiting until N simultaneous infections, with lower R0 longer chains of transmission affecting more individuals in total than R0 = 4. (B) These 1192

Figure:

R0 affects a pathogen’s evolutionary potential

(A) When waiting until an epidemic affects N = 16 people simultaneously, R0 = 1·5 has reproductive number in humans before evolution.

(B) Further adaptive evolution threatens to hamper control efforts through additional increases in R0 changes in the route of transmission, or shifts to presymptomatic or asymptomatic transmission. For most emerging zoonotic infections, the primary constraint on adaptive evolution will be the availability of suitable mutations in the pathogen population, which increase as a function of time.

R0 substantially affects the amount of time available for evolution before an epidemic reaches a critical size. A pathogen with a lower R0 has both longer chains of transmission and a greater number of total infections before reaching a given number of simultaneous infections than a pathogen with higher R0 (figure A). More generally, the length of the chain of transmission necessary to reach a threshold number of simultaneous infections (N) decreases with increasing R0 as \( \log_{10}(N) \), and a qualitatively similar relationship exists between total infections and R0 as \( (R_0N-1)/(R_0-1) \) (figure 1B).

If substantial public health resources are deployed only towards pathogens that have achieved high visibility by infecting a large number of people (i.e., a threshold number of infections), then we will miss a crucial window of opportunity to control low-R0 emerging pathogens. Because time constrains evolution, lower R0 (but still >1) pathogens have more opportunities to acquire advantageous mutations before an epidemic reaches a size at which the world becomes widely aware of the danger (figure 1C, top left corner).

For decades, monkeypox has been well known as an emerging infection with an R less than 1.7 Now its R is probably higher, which could be the result either of evolution within the animal reservoir population or within humans. Regardless, now is the time—probably past the time—to put resources into controlling outbreaks before they grow larger and have time to evolve further. For the current outbreak of monkeypox virus, the rapid use of ring vaccination, where index cases, traced contacts (of the index case), and contacts of those contacts are all vaccinated with the licensed MVA-BN vaccine (known as imvanex), could help to ensure that this epidemic does not get out of control. This vaccine plus unlicensed monkeypox vaccines could be randomly tested for efficacy in ring vaccination. Such a vaccination strategy led to the eradication of smallpox and could be quite effective in the still-early phase of the monkeypox outbreak.

In general, our analysis from first principles highlights the benefits of rapid intervention even for mild emerging pathogens. In summary, just because a disease like monkeypox appears to be controllable does not mean it will stay controllable. Currently, monkeypox incidence is starting to decrease in Europe and North America. This reduction might be due to behavioural changes in at-risk populations and increased use of vaccines, but the epidemic is far from over and continued drive towards elimination is essential.1 By reducing the chance of evolution, rapid and sustained intervention benefits not only local communities but also the world. That said, we considered the
evolutionary implications of delaying intervention without addressing trade-offs that arise due to the inherent scarcity of public health resources. Future research might need to account for both factors to find a balance between minimising delay to prevent virus evolution and increasing delay to ensure optimal resource allocation.

CTB received consulting fees from Color Health and honoraria from Novartis Oncology. All other authors declare no competing interests. This Correspondence was supported in part by the Swiss National Science Foundation (grant number 31003A_179170 to RRR) and the US National Institutes of Health (grant numbers U01 AI 150747 and U01 AI 144616 to RA).

*Philip L F Johnson, Carl T Bergstrom, Roland R Rques, Ira M Longini, M Elizabeth Halloran, Rustom Antia plfj@um.edu

Department of Biology, University of Maryland, College Park, MA 20742, USA (PLFJ); Department of Biology (CTB) and Department of Biostatistics (MEH), University of Washington, Seattle, WA, USA; Fred Hutchinson Cancer Center, Seattle, WA, USA (MEH); Institute of Integrative Biology, ETH Zurich, Zurich, Switzerland (RRR); Department of Biostatistics, University of Florida, Gainesville, FL, USA (IML); Department of Biology, Emory University, Atlanta, GA, USA (RA)

1 Urbanowicz RA, McClure CP, Sakuntabhai A, et al. Human adaptation of ebola virus during the west African outbreak. Cell 2016; 167: 1079–87.e5.
2 Hadfield J, Megill C, Bell SM, et al. Nextstrain: real-time tracking of pathogen evolution. Bioinformatics 2018; 34: 4211–23.
3 Nishiuha H, Ito K, Anzai A, Kobayashi T, Piantham C, Rodriguez-Morales AJ. Relative reproduction number of SARS-CoV-2 omicron (B.1.1.529) compared with delta variant in South Africa. J Clin Med 2021; 13: 30.
4 Isidro J, Borres V, Pinto M, et al. Phylogenetic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus. Nat Med 2022; 28: 1569–72.
5 Antia R, Rques RR, Koella JC, Bergstrom CT. The role of evolution in the emergence of infectious diseases. Nature 2003; 426: 659–61.
6 Rimoin AW, Mulembakani PM, Johnston SC, et al. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci USA 2010; 107: 16262–67.
7 Grant R, Nguyen LL, Bribian R. Modelling human-to-human transmission of monkeypox. Bull World Health Organ 2020; 98: 638–40.

WHO. Statement: control, eradication: three actions we need to take on three different public health emergencies in the European Region in the coming months. Aug 30, 2022. https://www.who.int/europe/news/item/30-08-2022-statement--control--eradication--three-actions-we-need-to-take-on-three-different-public-health-emergencies-in-the-european-region-in-the-coming-months (accessed Sept 1, 2022).

Monkeypox and pregnancy: time for global surveillance and prevention strategies

We read with interest the guidelines suggested by Pradith Dashraath and colleagues.1 We wish to highlight the potential for this monkeypox epidemic to encourage the introduction of global surveillance and prevention strategies. The monkeypox outbreak is of particular concern for pregnant women because infection could affect not only the mothers, but also their babies, by either prenatal vertical transmission or direct transmission after birth. Emerging paediatric cases are a cause for concern because pregnant women, young children, and people who are immunocompromised are considered at highest risk of severe monkeypox.

The fact that monkeypox was first identified in Africa in 1970, with thousands of suspected cases and deaths in the past decade, yet so little is known about its effects on pregnant women or pregnancy outcomes,1 the risk of vertical transmission, or the safety and effectiveness of vaccination in pregnant women, is an indictment of the international medical community. Several decades of opportunity to understand the prevention, surveillance, investigation, and management of monkeypox have been lost. Had appropriate attention been paid by international funding bodies and medical journals, pregnant populations in the endemic low and middle-income countries (LMICs) would have greatly benefited, and high-income countries would have been better prepared for the current outbreak.

Lessons must be learned: infectious diseases are likely to spread globally, so should be given appropriate medical focus at an early stage, to benefit both endemic LMICs and those high-income countries that will inevitably be affected sooner or later, ensuring maternal health-care equity.

AK and PO’B are members of the Royal College of Obstetricians and Gynaecologists’ group developing guidance on monkeypox in pregnancy. PO’B is Vice President of The Royal College of Obstetricians and Gynaecologists. All other authors declare no competing interests.

*Asma Khalil, Athina Samara, Shamez Ladhani, Pat O’Brien akhalil@sgul.ac.uk

Fetal Medicine Unit, St George’s Hospital, St George’s University of London, London SW17 0QT, UK (AK); Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute, St George’s University of London, London, UK (AK); Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden (AS); Astrid Lindgren Children’s Hospital, Karolinska University Hospital, Stockholm, Sweden (AS); Paediatric Infectious Diseases Research Group and Vaccine Institute, Institute of Infection and Immunity, St George’s University of London, London, UK (SL); Vascular Biology Research Centre, St George’s University of London, London SW17 0QT, UK (SL); British Paediatric Surveillance Unit, Royal College of Paediatrics and Child Health, London, UK (SL); The Royal College of Obstetricians and Gynaecologists, London, UK (PO’B); University College London Hospitals NHS Foundation Trust, London, UK (PO’B)

1 Dashraath P, Nielsen-Saines K, Mattar C, Musso D, Tarning P, Baud D. Guidelines for pregnant individuals with monkeypox virus exposure. Lancet 2022; 400: 21–22.
2 Mbala PK, Huguet J, Riou P, et al. Maternal and fetal outcomes among pregnant women with human monkeypox infection in the Democratic Republic of Congo. J Infect Dis 2022; 216: 834–28.

Protecting patients during a shortage of thrombolytic agents

Pulmonary embolism is a major cause of global death and disability.1 Pulmonary embolism with haemodynamic instability, defined by European Society of Cardiology